Structured evidence table for Alpha Gpc Cognitive Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Alpha Gpc Cognitive Performance Randomized Trial | Next, we integrate evidence on the ergogenic effects of various dietary interventions with existing knowledge on the perception of effort. | 4 | Strasser B (2026) | Dietary interventions interact with the perception of effort and enhance endurance performance: a brief narrative review. |
| Alpha Gpc Cognitive Performance Randomized Trial | Beta-alanine, caffeine or carbohydrate mouth rinsing are examples of evidence-based ergogenic aids. | 4 | Strasser B (2026) | Dietary interventions interact with the perception of effort and enhance endurance performance: a brief narrative review. |
| Alpha Gpc Cognitive Performance Randomized Trial | Conclusion While current evidence supports a key role for dietary interventions on endurance performance by influencing individuals' perceived effort, more research is needed to determine the optimal doses and precise formulations for different sports, in order to employ a personalized strategy. | 4 | Strasser B (2026) | Dietary interventions interact with the perception of effort and enhance endurance performance: a brief narrative review. |
| Alpha Gpc Cognitive Performance Randomized Trial | Background Exercise tolerance is a pivotal factor in determining athletic competitive success, as well as mobility and quality of life in elderly individuals and those afflicted by chronic ailments. | 4 | Strasser B (2026) | Dietary interventions interact with the perception of effort and enhance endurance performance: a brief narrative review. |
| Alpha Gpc Cognitive Performance Randomized Trial | Although L-α-GPC has been discussed in both neurodegenerative and vascular-related cognitive disorders, the available evidence remains heterogeneous. | 4 | Putri Vannisa Artasya (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders |
| Alpha Gpc Cognitive Performance Randomized Trial | Therefore, a careful and contextualized interpretation of the literature is necessary, particularly when comparing evidence across Alzheimer’s disease, Parkinson’s disease-related cognitive decline, and cognitive impairment associated with cerebrovascular conditions. | 4 | Putri Vannisa Artasya (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders |
| Alpha Gpc Cognitive Performance Randomized Trial | Given this background, the present narrative review focuses primarily on the mechanistic and clinical evidence regarding L-α-GPC in cognitive decline associated with neurodegenerative disorders, while also acknowledging relevant findings from studies of vascular- or cerebrovascular-related cognitive impairment where appropriate. | 4 | Putri Vannisa Artasya (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders |
| Alpha Gpc Cognitive Performance Randomized Trial | 1 2 Neurodegeneration involves the progressive loss of neuronal structure and function, leading to cognitive and motor impairments. | 4 | Putri Vannisa Artasya (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders |
Source documents